AZD4573   Click here for help

GtoPdb Ligand ID: 11782

Synonyms: AZD-4573 | compound 24 [PMID: 33306391]
PDB Ligand
Compound class: Synthetic organic
Comment: AZD4573 is a potent inhibitor of cyclin dependent kinase 9 (CDK9), that was designed for potential to treat haematological malignancies [1-3]. Inhibition of CDK9 disrupts the expression of cancer-promoting genes such as MCL-1, and induces apoptosis.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 88.91
Molecular weight 429.19
XLogP 3.17
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1ncc(c(c1)c1cnn2c1CC(C2)(C)C)Cl
Isomeric SMILES CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1ncc(c(c1)c1c2CC(Cn2nc1)(C)C)Cl
InChI InChI=1S/C22H28ClN5O2/c1-13(29)26-15-6-4-5-14(7-15)21(30)27-20-8-16(18(23)11-24-20)17-10-25-28-12-22(2,3)9-19(17)28/h8,10-11,14-15H,4-7,9,12H2,1-3H3,(H,26,29)(H,24,27,30)/t14-,15+/m0/s1
InChI Key AVIWDYSJSPOOAR-LSDHHAIUSA-N
No information available.
Summary of Clinical Use Click here for help
AZD4573 has progressed to clinical evaluation, to determine efficacy in the treatment of advanced haematological malignancies.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03263637 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Phase 1 Interventional AstraZeneca
NCT04630756 AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer. Phase 1/Phase 2 Interventional AstraZeneca